NeoGenomics Is Maintained at Neutral by B of A Securities

Dow JonesDec 13 11:08 ET · Ratings

BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Raises Target Price to $19

Moomoo NewsDec 13 08:31 ET · Ratings

NeoGenomics Study Highlights CtDNA's Potential To Predict Recurrence In High-Risk Melanoma; RaDaR Sequencing Assay Identifies Molecular Residual Disease Across Broader Patient Range, Enabling Earlier Detection And Prognosis Monitoring

BenzingaDec 11 08:08 ET

NeoGenomics' Newly Published Study Underscores Potential of CtDNA as a Predictive Tool for Monitoring Patients With High-Risk Melanoma

BusinesswireDec 11 08:05 ET

Strong Week for NeoGenomics (NASDAQ:NEO) Shareholders Doesn't Alleviate Pain of Three-year Loss

Simply Wall StDec 11 06:57 ET

NeoGenomics Analyst Ratings

BenzingaDec 10 10:59 ET · Ratings